Department of Critical Care Medicine, University of Poitiers, CHU, Poitiers, F86000, France.
Ann Intensive Care. 2012 Aug 23;2(1):40. doi: 10.1186/2110-5820-2-40.
Lowering the temperature setting in the heating device during continuous venovenous hemofiltration (CVVH) is an option. The purpose of this study was to determine the effects on body temperature and hemodynamic tolerance of two different temperature settings in the warming device in patients treated with CVVH.
Thirty patients (mean age: 66.5 years; mean SAPS 2: 55) were enrolled in a prospective crossover randomized study. After a baseline of 2 h at 38°C, the heating device was randomly set to 38°C (group A) and 36°C (group B) for 6 h. Then, the temperatures were switched to 36°C in group A and to 38°C in group B for another 6 h. Hemodynamic parameters and therapeutic interventions to control the hemodynamics were recorded.
There was no significant change in body temperature in either group. During the first 6 h, group B patients showed significantly increased arterial pressure (p = 0.01) while the dosage of catecholamine was significantly decreased (p = 0.04). The number of patients who required fluid infusion or increase in catecholamine dosage was similar. During the second period of the study, hemodynamic parameters were unchanged in both groups.
In patients undergoing CVVH, warming of the substitute over 36°C had no impact on body temperature. We showed that setting the fluid temperature at 36°C for a period of time early in the procedure is beneficial in terms of increased mean arterial pressure and decreased catecholamine infusion dosage.
在连续静脉-静脉血液滤过(CVVH)过程中降低加热设备的温度设置是一种选择。本研究的目的是确定在接受 CVVH 治疗的患者中,加热设备中两种不同温度设置对体温和血液动力学耐受性的影响。
30 名患者(平均年龄:66.5 岁;平均 SAPS 2:55)被纳入前瞻性交叉随机研究。在 38°C 下进行 2 小时的基线后,将加热设备随机设置为 38°C(A 组)和 36°C(B 组),持续 6 小时。然后,将温度切换到 A 组的 36°C 和 B 组的 38°C,再持续 6 小时。记录血液动力学参数和控制血液动力学的治疗干预措施。
两组患者的体温均无明显变化。在最初的 6 小时内,B 组患者的动脉压显著升高(p=0.01),而儿茶酚胺的剂量显著降低(p=0.04)。需要输液或增加儿茶酚胺剂量的患者数量相似。在研究的第二阶段,两组患者的血液动力学参数均无变化。
在接受 CVVH 的患者中,将替代液加热至 36°C 以上不会影响体温。我们表明,在程序早期将液体温度设置为 36°C 一段时间,有利于增加平均动脉压和减少儿茶酚胺输注剂量。